Renal Business Today

Venofer

DaVita Named in Whistleblower Lawsuit

ATLANTA—In a whistleblower lawsuit, dialysis provider DaVita has been accused of intentionally throwing away extra medication in order to boost reimbursements from Medicare and Medicaid. ...More
July 27, 2011
Posted in News, Government & Regulation
Global IV Iron Drug Market to Reach $1.6 Billion by 2015

SAN JOSE, Calif.—The global market for Intravenous (IV) Iron Drugs is forecast to reach $1.6 billion by the year 2015, according to a report market research company Global Industry Analysts Inc. (GIA). ...More
August 10, 2010
Posted in News, Business, Clinical & Pharma
Anemia Study Changed Way Docs Prescribe ESAs

EXTON, Pa.—Recent clinical reports on erythropoietin-stimulating agents have changed the way nephrologists are prescribing anemia drugs, according to recent survey results from BioTrends Research ...More
April 27, 2010
Posted in News, Business, Clinical & Pharma, Practice Management
Use of AMAG’s Feraheme on the Rise

EXTON, Pa.— Six months after launching, the use of AMAG Pharmaceuticals' Feraheme is on the rise with 23 percent of nephrologists reporting use of the IV iron drug, according to new survey results from BioTrends Research Group. ...More
February 16, 2010
Posted in News, Business, Clinical & Pharma, Practice Management
Future Iron Treatments Shaped by New Payment Structures, Products

The choice of what iron product to use will be especially relevant with the bundled payment set to start in 2011. According to an August 2009 BioTrends report, dialysis clinic medical directors foresee the increased use of IV iron to spare the use of ESAs (such as Amgen’s ...More
January 29, 2010
Posted in Articles, Business, Clinical & Pharma, Practice Management
Many New ESRD Patients Haven’t Seen Nephrologist

WASHINGTON—In 2007, many patients starting end-stage renal disease therapy received no nephrologist care, dietary counseling or therapy with erythropoietin-stimulating agents prior to treatment, suggesting that the transition to ESRD is poor in the United States, according ...More
September 23, 2009
Posted in News, Business, Clinical & Pharma, Government & Regulation
Report: Product Shifts in Renal Anemia, Bone, Mineral Metabolism Markets

EXTON, Pa.—Product shifts are occurring in the renal anemia and bone and mineral metabolism markets, according to BioTrends Research Group’s most recent TreatmentTrends®: US Nephrology Report syndicated report based on online survey results of more than 200 ...More
April 28, 2009
Posted in News, Business, Clinical & Pharma, Practice Management
DaVita Gets DOJ Subpoena over Drug Claims

EL SEGUNDO, Calif.—Dialysis provider DaVita Inc. said Monday that it working to produce a wide range of documents related to pharmaceutical products in response to a federal subpoena that is connected to a civil investigation. ...More
December 15, 2008
Posted in News, Business, Clinical & Pharma, Government & Regulation
Top 10 Renal Stories of 2008

Years come and years go, but 2008 will long be remembered as the year that shaped the renal community for the 21st century. It was the year that the End-Stage Renal Disease Program saw some of its biggest changes in three decades, from the updated Conditions for Coverage as ...More
December 2, 2008
Posted in Articles, Business, Clinical & Pharma, Government & Regulation, Practice Management
Number of U.S. ESRD patients exceeds 500,000

In 2006, more than 500,000 patients received some form of end-stage renal disease therapy in the United States, and Medicare spent nearly $23 billion to care for them, according to the U.S. Renal Data System’s 2008 Annual Data Report. ...More
September 19, 2008
Posted in News, Business, Clinical & Pharma

featured links

HOT TOPICS

Computers & Software	Consulting, Management...
Equipment & Services	Hemodialysis Supplies
Patient Services	More Options...

Venofer

Mobile Health Snaps

Galleries

Most Popular Articles

Buyer's Guide

Resources

Free Email Updates

featured links

First Name	Last Name
E-Mail